Skip to main content

Table 3 Patient demographics and baseline characteristics from extension study baseline

From: Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

  3003 ApoE ε4 carrier study 3002 ApoE ε4 noncarrier study
PBO + BAP 0.5 (n = 215) BAP 0.5 + BAP 0.5 (n = 275) PBO + BAP 0.5 (n = 39) PBO + BAP 1.0 (n = 37) BAP 0.5 + BAP 0.5 (n = 66) BAP 1.0 + BAP 1.0 (n = 56)
Mean age (years) 71.4 72.1 68.7 68.9 71.4 70.6
Femalea (%) 62.8 67.6 64.1 59.5 53.0 62.5
Whitea (%) 79.5 75.6 76.9 81.1 74.2 66.1
Asian (%) 18.1 22.9 23.1 18.9 25.8 32.1
Mean duration of AD (years) 4.49 4.58 4.16 4.50 4.44 4.46
Mean baseline MMSE 19.0b 19.2 18.6c 17.1 19.1 18.4
Current AChEI and/or memantine use, n (%)
 Yes 193 (89.8) 242 (88.0) 34 (87.2) 31 (83.8) 51 (77.3) 53 (94.6)
 No 22 (10.2) 33 (12.0) 5 (12.8) 6 (16.2) 15 (22.7) 3 (5.4)
  1. AChEI acetylcholinesterase inhibitor, AD Alzheimer’s disease, ApoE apolipoprotein E, BAP bapineuzumab, MMSE Mini-Mental State Examination, PBO placebo
  2. aA few patients may have been misclassified at baseline, causing discrepancy with Table 2: one patient was classified as male at parent baseline and female at extension baseline; three patients were classified as white at parent baseline and Asian or “other” at extension baseline
  3. b n = 212
  4. c n = 38